| Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma (NCT04417166) | International Extranodal Lymphoma Study Group (IELSG) | 2022-02-11 |
| Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] (NCT03439501) | Samsung Medical Center | 2018-01-16 |
| GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma (NCT03154918) | Sichuan University | 2017-06-01 |
| T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas (NCT03049449) | National Cancer Institute (NCI) | 2017-03-17 |
| 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma (NCT03051555) | Peking University Cancer Hospital & Institute | 2017-03-01 |
| Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma (NCT03051542) | Peking University Cancer Hospital & Institute | 2017-03-01 |
| Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas (NCT02859402) | Keimyung University Dongsan Medical Center | 2016-12-01 |
| AEDV Registry of Primary Cutaneous Lymphoma (NCT03646422) | Fundación Academia Española de Dermatología | 2016-09-01 |
| Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation (NCT02878278) | Huiqiang Huang | 2016-09-01 |
| Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage (NCT02359162) | Sun Yat-sen University | 2015-05-01 |
| Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma (NCT01948180) | Cell Medica Ltd | 2014-09-01 |
| Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL (NCT02080234) | Sun Yat-sen University | 2014-03-01 |
| MESA Treatment for NK/T Cell Lymphoma (NCT01933282) | Air Force Military Medical University, China | 2013-01-01 |
| P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens (NCT02533323) | Sun Yat-sen University | 2012-01-01 |
| Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas (NCT00069238) | National Cancer Institute (NCI) | 2003-09-19 |